2022-08-15| M&A

Ipsen Completes $247 Million Oncology Buyout Of Epizyme

by Joy Lin
Share To

French drugmaker Ipsen has completed its $247 million takeover of US-based Epizyme, bringing in FDA-approved cancer medication, Tazverik (tazemetostat), as well as a pipeline of oncology and epigenetic assets. 

Originally announced in June, the acquisition saw Ipsen acquire all shares in Epizyme for $1.45 per share plus a contingent value right of $1.00 per share. 

Related article:Potential $1 billion Acquisition of TeneoTwo by AstraZeneca comes to Fruition

Treatments For Lymphoma and Myeloma

Joining Ipsen’s oncology portfolio is Tazverik, an EZH2 inhibitor granted accelerated approval by the US FDA in 2020. Tazverik is currently indicated for patients with relapsed or refractory follicular lymphoma (FL) who have EZH2 mutations and have received at least two systemic therapies. It is also approved for FL patients with no alternative treatment options and patients with advanced epithelioid sarcoma that cannot be surgically removed. 

Besides Tazverik, Ipsen will also get Epizyme’s oral SETD2 inhibitor candidate, EZM0414, which was granted FDA Fast Track Status in 2021 and is currently in a Phase 1/1b in multiple myeloma and diffuse large B-cell lymphoma. 

Lastly, Ipsen will take over a number of preclinical programs focusing on epigenetics, an approach where chromatin-modifying proteins modulate DNA and its associated proteins. 

Cost Reductions And Job Cuts

By acquiring Epizyme, Ipsen will be responsible for expanding indications for Tazverik, which is currently held back by small patient populations. 

The drug earned just $31 million for Epizyme last year, compared to a net loss of $250 million which saw the company slash part of its workforce and end clinical studies in an effort to cut costs. 

© All rights reserved. Collaborate with us:
Related Post
Previewing AACR 2024 With Select Pre-Meeting Highlights
AbbVie Boosts Global Manufacturing with $223 Million Expansion in Singapore
JPM 2024: Pfizer’s Strategic Moves in the Obesity Drug Market and BioNTech’s Oncology Pipeline Expansion
New Regulatory Measures in China A First in the Fight Against Sedentary Behavior in Children
Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at ASGCT 2024
AstraZeneca’s $1.5 Billion ADC Manufacturing Facility in Singapore
Hims & Hers Health Inc. Tipping the Scales of the Weight Loss Market — and Wall Street is Loving it!
GV Announces Cooperation with CICC
Eli Lilly and Aktis Oncology Partner to Advance Novel Radiopharmaceuticals
Preventive Medicine for Neurodegeneration on the Rise: New Breakthrough in Routine Blood Testing for Alzheimer’s Disease
Scroll to Top